JP2024514942A5 - - Google Patents

Info

Publication number
JP2024514942A5
JP2024514942A5 JP2023564432A JP2023564432A JP2024514942A5 JP 2024514942 A5 JP2024514942 A5 JP 2024514942A5 JP 2023564432 A JP2023564432 A JP 2023564432A JP 2023564432 A JP2023564432 A JP 2023564432A JP 2024514942 A5 JP2024514942 A5 JP 2024514942A5
Authority
JP
Japan
Prior art keywords
tkis
immune cells
cells
culture
cars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/071845 external-priority patent/WO2022226522A1/en
Publication of JP2024514942A publication Critical patent/JP2024514942A/ja
Publication of JP2024514942A5 publication Critical patent/JP2024514942A5/ja
Pending legal-status Critical Current

Links

JP2023564432A 2021-04-22 2022-04-21 殺夾雑活性を低下させた免疫細胞を工学的に作製する方法 Pending JP2024514942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178351P 2021-04-22 2021-04-22
US63/178,351 2021-04-22
PCT/US2022/071845 WO2022226522A1 (en) 2021-04-22 2022-04-21 Methods of engineering immune cells having reduced fratricidal activity

Publications (2)

Publication Number Publication Date
JP2024514942A JP2024514942A (ja) 2024-04-03
JP2024514942A5 true JP2024514942A5 (cg-RX-API-DMAC7.html) 2025-03-10

Family

ID=83723256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564432A Pending JP2024514942A (ja) 2021-04-22 2022-04-21 殺夾雑活性を低下させた免疫細胞を工学的に作製する方法

Country Status (7)

Country Link
US (1) US20240382521A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326293A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514942A (cg-RX-API-DMAC7.html)
CN (1) CN117545492A (cg-RX-API-DMAC7.html)
AU (1) AU2022262088A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217028A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226522A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN115651903B (zh) * 2022-11-14 2023-03-17 四川新生命干细胞科技股份有限公司 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
WO2024163619A1 (en) * 2023-02-01 2024-08-08 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
CN119506184A (zh) * 2023-08-22 2025-02-25 深圳赛桥生物创新技术有限公司 细胞制剂处理方法、装置、系统和介质

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ,インコーポレイテッド 胚性幹細胞血清置換
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020168766A1 (en) 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1412479A4 (en) 2001-07-12 2004-07-28 Geron Corp CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
US11390658B2 (en) 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
GB201622044D0 (en) 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells

Similar Documents

Publication Publication Date Title
JP7504957B2 (ja) アレル編集およびその応用
Pezoldt et al. Neonatally imprinted stromal cell subsets induce tolerogenic dendritic cells in mesenteric lymph nodes
McHeyzer-Williams et al. Class-switched memory B cells remodel BCRs within secondary germinal centers
JP2022184852A5 (cg-RX-API-DMAC7.html)
Bansal et al. IL‐21 enhances the potential of human γδ T cells to provide B‐cell help
JP2019536461A5 (cg-RX-API-DMAC7.html)
Liu et al. CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ Treg cells
RU2019128544A (ru) Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN110603320B (zh) 高活性nk细胞及其应用
JP2021180674A (ja) 免疫グロブリン産生の増強
JP2018514204A5 (cg-RX-API-DMAC7.html)
JP2021522839A5 (cg-RX-API-DMAC7.html)
WO2023278811A1 (en) Engineered natural killer (nk) cells and related methods
JP2022542399A5 (cg-RX-API-DMAC7.html)
JP2023539361A5 (cg-RX-API-DMAC7.html)
Preite et al. Somatic mutations and affinity maturation are impaired by excessive numbers of T follicular helper cells and restored by Treg cells or memory T cells
WO2020259707A1 (zh) 抗移植反应的细胞和方法
MX2012013437A (es) Metodo de cultivo de celulas b individuales.
JP2020507349A5 (cg-RX-API-DMAC7.html)
FI3835415T3 (fi) Menetelmä cd3-positiivisen solun tuottamiseksi
JP2022522231A (ja) 抗bcma car t細胞の製造
JP2022512922A5 (cg-RX-API-DMAC7.html)
JP2022524882A5 (cg-RX-API-DMAC7.html)
US20090217403A1 (en) Means and methods for generating a t cell against an antigen of interest
JP2020535832A (ja) マウス定常領域を伴うtcrを発現する細胞を選択的に増幅するための方法